In Italy, the same brand name can appear in very different funding situations. What matters is why the medicine is prescribed and which coverage conditions apply. An answer that leaves out the purpose of treatment can be misleading even when the ingredient is correctly identified.

Always include the indication in your cost question

AIFA describes Wegovy, Saxenda and Mounjaro used for weight management as not reimbursed by Italy’s national health service, the SSN. For this use, the agency identifies Class C status and payment by the patient. The relevant information was published on 18 May 2026.

For type 2 diabetes, AIFA lists medicines including Mounjaro, Ozempic and Rybelsus as reimbursable under Note 100. That is not a blanket promise for every person or every use. Diabetes care and treatment specifically for weight management should not be treated as the same funding situation.

Questions to ask before prescribing

Ask the treating practice to explain what the medicine is intended to achieve in your case. Clarify the indication under which it would be prescribed and whether the relevant national reimbursement conditions have been assessed. A change in weight as an additional effect is not automatically the purpose of a prescription.

Request the exact formulation and pack being considered. If several options are discussed, keep separate notes for each. Clinical decisions should reflect benefits, risks and your circumstances; an insurance route is not a reason to reinterpret a diagnosis to fit a bill.

Budget for the whole course of care

Ask for a current price for the pack actually prescribed. Separately check the initial consultation, follow-up appointments and agreed nutritional counselling. Establish whether these services will be provided publicly, charged privately or covered through another confirmed arrangement.

A pack covering four weeks is not necessarily the same as a calendar month. Have the supply period explained rather than multiplying an advertising figure by twelve. The cost calculator on this website therefore uses your own entries and does not provide a binding pharmacy price.

Distinguish approval from actual availability

European information may already describe new forms before the practical national supply situation is clear. The EMA overview of Wegovy now includes tablets for adults. That does not automatically establish which Italian pack is on sale or reimbursable.

Ask the pharmacy about the exact prescribed form. A product missing locally may reflect a local ordering problem. AIFA’s Farmaci carenti list helps identify reported shortages, but it does not replace a reliable stock answer from the pharmacy supplying you.

Why an online offer is not a shortcut

AIFA explicitly states that these prescription medicines cannot be purchased online in Italy. The Ministry of Health’s register of lawful online retailers concerns non-prescription medicines. A listing or safety logo therefore does not validate online sales of a prescription weight-loss injection.

Product photographs and supposed customer testimonials cannot establish authenticity when an offer looks suspicious. Use the regular pharmacy supply chain. If costs become difficult, discuss your care with the treatment team instead of turning to social media, private resales or unfamiliar import sources.

Common questions

Is Mounjaro paid for in Italy or not?

The answer needs the indication. AIFA distinguishes reimbursable type 2 diabetes treatment under Note 100 from self-funded weight management. The exact product and the conditions currently in force also need checking. A brand name alone cannot settle your personal funding question.

Can an overseas price predict what I will pay?

No. Packs, national availability, insurance and additional services can differ. Request specific information from the Italian pharmacy and your practice. If care crosses national borders, clarify the financial arrangements with your insurer before obtaining the medicine rather than assuming domestic coverage follows you.

Sources & further reading

  1. AIFA: New medicines for type 2 diabetes and obesity, 18.05.2026
  2. AIFA: FarmaciLine
  3. AIFA: Farmaci carenti
  4. Ministero della Salute: elenco delle farmacie online autorizzate
  5. EMA: Wegovy
  6. EMA: Mounjaro

Sources checked:

eu. infopoint editorial team

Researched and created with AI assistance. This article has not undergone individual review by a medical professional.

About our health information

Published:

Report a correction

Questions and experiences

Share a question or a useful experience about this topic. Every contribution is checked before publication. Comments may be written in different languages.

Loading reader contributions…

Opening the form sets a necessary session cookie. No email address is required. Publication is subject to moderation and is not guaranteed. For deletion requests: Contact